Neurorobiology and evidence-based biological treatments for substance abuse disorders

CNS Spectrums

Volumn 11, Issue 11, 2006, Pages 864-877

  Ivanov, Iliyan S ^a   Schulz, Kurt P ^a   Palmero, Robyn C ^b   Newcorn, Jeffrey H ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MSSM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ADRENALIN; ADROGOLIDE; ALCOHOL; AMFEBUTAMONE; ARIPIPRAZOLE; BP 897; CANNABINOID; DELTA OPIATE RECEPTOR; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; GLUTAMIC ACID; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NORADRENALIN UPTAKE INHIBITOR; OPIATE RECEPTOR; SEROTONIN; SEROTONIN RECEPTOR; UNINDEXED DRUG; VANOXERINE;

COMPULSION; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; GABAERGIC SYSTEM; HUMAN; HYPOTHESIS; NEUROBIOLOGY; NEUROPSYCHIATRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROBABILITY; RELAPSE; REVIEW; SOCIAL INTERACTION; SUBSTANCE ABUSE;

EID: 33751574267     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900015017     Document Type: Review

References (145)

1. Baldessarini RJ, Tarazi FI. Brain dopamine receptors: a primer on their current status, basic and clinical. Harv Rev Psychiatry. 1996;3:301-325.
2. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278:52-58.
3. Lubman DI, Yucel M, Pantelis C. Addiction, a condition of compulsive behaviour? Neuroimaging and neuropsychological evidence of inhibitory dysregulation. Addiction. 2004;99:1491-1502.
4. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18:247-291.
5. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction. 2000;95(suppl 2):S91-S117.
6. Winger G, Woods JH, Galuska CM, Wade-Galuska T. Behavioral perspectives on the neuroscience of drug addiction. J Exp Anal Behav. 2005;84:667-681.
7. Aron AR, Bobbins TW, Poldrack RA. Inhibition and the right inferior frontal cortex. Trends Cogn Sci. 2004;8:170-177.
8. McClure SM, Laibson DI, Loewenstein G, Cohen JD. Separate neural systems value immediate and delayed monetary rewards. Science. 2004;306:503-507.
9. Nigg JT. Response inhibition and disruptive behaviors: toward a multiprocess conception of etiological heterogeneity for ADHD combined type and conduct disorder early-onset type. Ann N Y Acad Sci. 2003;1008:170-182.
10. Sonuga-Barke EJ. The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev. 2003;27:593-604.
11. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12:483-488.
12. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237:1219-1223.
13. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry. 1995;52:456-463.
14. Di Chiara G. Alcohol and dopamine. Alcohol Health Res World. 1997;21:108-114.
15. Dackis CA, Gold MS. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev. 1985;9:469-477.
16. Salamone JD, Cousins MS, Snyder BJ. Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis. Neurosci Biobehav Rev. 1997;21:341-359.
17. Berridge KC, Robinson TE. Parsing reward. Trends Neurosci. 2003;26:507-513.
18. Di Chiara G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol. 1998;12:54-67.
19. Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36:241-263.
20. Self DW, Nestler EJ. Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend. 1998;51:49-60.
21. Self DW. Regulation of drug-taking and -seeking behaviors by neuroadaptations in the mesolimbic dopamine system. Neuropharmacology. 2004;47(suppl 1):242-255.
22. Caravan H, Pankiewicz J, Bloom A, et al. Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry. 2000;157:1789-1798.
23. Martin-Soelch C, Chevalley AF, Kunig G, et al. Changes in reward-induced brain activation in opiate addicts. Eur J Neurosci. 2001;14:1360-1368.
24. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry. 2001;49:81-96.
25. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121.
26. Volkow ND, Wang GJ, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse. 2002;43:181-187.
27. Boileau I, Assaad JM, Pihl RO, et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse. 2003;49:226-231.
28. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9:557-569.
29. Volkow ND, Wang GJ, Fowler JS, et al. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse. 2002;46:79-82.
30. Schilstrom B, Svensson HM, Svensson TH, Nomikos GG. Nicotine and food induced dopamine release in the nucleus accumbens of the rat: putative role of alpha7 nicotinic receptors in the ventral tegmental area. Neuroscience. 1998;85:1005-1009.
31. Koob GF. Cocaine reward and dopamine receptors: love at first site. Arch Gen Psychiatry. 1999;56:1107-1108.
32. Wise RA. Opiate reward: sites and substrates. Neurosci Biobehav Rev. 1989;13:129-133.
33. Yim HJ, Gonzales RA. Ethanol-induced increases in dopamine extracellular concentration in rat nucleus accumbens are accounted for by increased release and not uptake inhibition. Alcohol. 2000;22:107-115.
34. Pich EM, Pagliusi SR, Tessari M, Talabot-Ayer D, Hooft van Huijsduijnen R, Chiamulera C. Common neural substrates for the addictive properties of nicotine and cocaine. Science. 1997;275:83-86.
35. Maisonneuve IM, Kreek MJ. Acute tolerance to the dopamine response induced by a binge pattern of cocaine administration in male rats: an in vivo microdialysis study. J Pharmacol Exp Ther. 1994;268:916-921.
36. Mill J, Asherson P, Browes C, D'Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet. 2002;114:975-979.
37. Haertzen CA, Kocher TR, Miyasato K. Reinforcements from the first drug experience can predict later drug habits and/or addiction: results with coffee, cigarettes, alcohol, barbiturates, minor and major tranquilizers, stimulants, marijuana, hallucinogens, heroin, opiates and cocaine. Drug Alcohol Depend. 1983;11:147-165.
38. Lott DC, Kim SJ, Cook EH Jr, de Wit H. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005;30:602-609.
39. Warsi M, Sattar SP, Bhatia SC, Petty F. Aripiprazole reduces alcohol use. Can J Psychiatry. 2005;50:244.
40. Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol. 2005;25:363-366.
41. Steele C. Zyban: an effective treatment for nicotine addiction. Hosp Med. 2000;61:785-788.
42. White WD, Crockford D, Patten S, El-Guebaly N. A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine Tob Res. 2005;7:809-813.
43. Montoya ID, Preston KL, Rothman R, Gorelick DA. Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence. Am J Drug Alcohol Abuse. 2002;28:189-196.
44. Chan-Ob T, Kuntawongse N, Boonyanaruthee V. Bupropion for amphetamine withdrawal syndrome. J Med Assoc Thai. 2001;84:1763-1765.
45. Solhkhah R, Wilens TE, Daly J, Prince JB, Van Patten SL, Biederman J. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol. 2005;15:777-786.
46. Gorelick DA, Gardner EL, Xi ZX. Agents in development for the management of cocaine abuse. Drugs. 2004;64:1547-1573
47. Mayer P, Hollt V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics. 2006;16:1-7.
48. Fattore L, Cossu G, Spano MS, et al. Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol. 2004;16:147-158.
49. Ciccocioppo R, Economidou D, Fedeli A, et al. Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology (Berl). 2004;172:170-178.
50. Kuzmin A, Kreek MJ, Bakalkin G, Liljequist S. The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking. Neuropsychopharmacology. In press.
51. Ghozland S, Matthes HW, Simonin F, Filliol O, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci. 2002;22:1146-1154.
52. Tao R, Auerbach SB. Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain. Neuroscience. 1995;68:553-561.
53. Kalyuzhny AE, Wessendorf MW. Relationship of mu- and delta-opioid receptors to GABAergic neurons in the central nervous system, including antinociceptive brainstem circuits. J Comp Neurol. 1998;392:528-547
54. Mansour A, Watson SJ, Akil H. Opioid receptors: past, present and future. Trends Neurosci. 1995;18:69-70.
55. Martin-Schild S, Gerall AA, Kastin AJ, Zadina JE. Differential distribution of endomorphin 1- and endomorphin 2-like immunoreactivities in the CNS of the rodent. J Comp Neurol. 1999;405:450-471.
56. Tork I. Anatomy of the serotonergic system. Ann N Y Acad Sci. 1990;600:9-34.
57. Benloucif S, Keegan MJ, Galloway MP. Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther. 1993;265:373-377.
58. Guan XM, McBride WJ. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull. 1989;23:541-547.
59. Rocha BA, Fumagalli F, Gainetdinov RR, et al. Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci. 1998;1:132-137.
60. Uhl GR, Hall FS, Sora I. Cocaine, reward, movement and monoamine transporters. Mol Psychiatry. 2002;7:21-26.
61. Weiss F, Mitchiner M, Bloom FE, Koob GF. Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide. Psychopharmacology (Berl). 1990;101:178-186.
62. Haigler HJ. Morphine: effects on serotonergic neurons and neurons in areas with a serotonergic input. Eur J Pharmacol. 1978;51:361-376.
63. Jolas T, Aghajanian GK. Neurotensin and the serotonergic system. Prog Neurobiol. 1997;52:455-468.
64. Tao R, Auerbach SB. Increased extracellular serotonin in rat brain after systemic or intraraphe administration of morphine. J Neurochem. 1994;63:517-524
65. Tao R, Ma Z, Auerbach SB. Differential effect of local infusion of serotonin reuptake inhibitors in the rapbe versus forebrain and the role of depolarization-induced release in increased extracellular serotonin. J Pharmacol Exp Ther. 2000;294:571-579.
66. Altshuler HL, Phillips PE, Feinhandler DA. Alteration of ethanol self-administration by naltrexone. Life Sci. 1980;26:679-688.
67. Altshuler HL. Behavioral methods for the assessment of alcohol tolerance and dependence. Drug Alcohol Depend. 1979;4:333-346.
68. Farre M, Mas A, Torrens M, Moreno V, Cami J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 2002;65:283-290.
69. Glanz M, Klawansky S, McAullife W, Chalmers T. Methadone vs L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction A meta-analysis of the randomized, controlled trials. Am J Addict. 1997;6:339-349.
70. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216.
71. Green H, James RA, Gilbert JD, Harpas P, Byard RW. Methadone maintenance programs - a two-edged sword? Am J Forensic Med Pathol. 2000;21:359-361.
72. Musshoff F, Lachenmeier DW, Madea B. Methadone substitution: medicolegal problems in Germany. Forensic Sci Int. 2003;133:118-124.
73. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14:747-753.
74. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355:365-374.
75. Ebner R, Schreiber W, Zierer C. Buprenorphine or methadone for detoxification of young opioid addicts? [German]. Psychiatr Prax. 2004;31(suppl 1):S108-S110.
76. Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, Brooklyn J. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005;62:1157-1164.
77. Verrando R, Robaeys G, Mathei C, Buntinx F. Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use. Acta Gastroenterol Belg. 2005;68:81-85
78. Raistrick D, West D, Finnegan O, Thistlethwaite G, Brearley R, Banbery J. A comparison of buprenorphine and lofexidine for community opiate detoxification: results from a randomized controlled trial. Addiction. 2005;100:1860-1867.
79. Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics. 2005;23:77-91.
80. Digiusto E, Lintzeris N, Breen C, et al. Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. Addict Behav. 2005;30:443-456.
81. Cook S, Indig D, Gray J, McGrath D. Opiate overdose and health treatment options for opiate users in New South Wales, 1999-2002. N S W Public Health Bull. 2004;15:125-131.
82. Simoens S, Matheson C, Bond C, Inkster K, Ludbrook A. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract. 2005;55:139-146.
83. Doran CM, Shanahan M, Bell J, Gibson A. A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal. Drug Alcohol Rev. 2004;23:171-175.
84. Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176:530-534.
85. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96:1565-1573.
86. O'Malley SS, Rounsaville BJ, Farren C, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med. 2003;163:1695-1704.
87. Deas D, May MP, Randall C, Johnson N, Anton R. Naltrexone treatment of adolescent alcoholics: an open-label pilot study. J Child Adolesc Psychopharmacol. 2005;15:723-728.
88. Roozen HG, de Waart R, van der Windt DA, van den Brink W, de Jong CA, Kerkhof AJ. A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur Neuropsychopharmacol. 2006;16:311-323.
89. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA and the Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345:1734-1739.
90. West SL, Garbutt JC, Carey TS, et al. Pharmacotherapy for alcohol dependence. Evid Rep Technol Assess (Summ). 1999;(3):1-5.
91. Feeney GF, Connor JP, Young RM, Tucker J, McPherson A. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. 2006;41:321-327.
92. Anton RF, O'Malley SS, Ciraulo DA, et al, and COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-2017.
93. Anton RF, Swift RM. Current pharmacotherapies of alcoholism: a U.S. perspective. Am J Addict. 2003;12(suppl 1):S53-S68.
94. Kiefer F, Wiedemann K. Combined therapy: what does acamprosate and naltrexone combination tell us? Alcohol Alcohol. 2004;39:542-547.
95. Williams SH. Medications for treating alcohol dependence. Am Fam Physician. 2005;72:1775-1780.
96. Johnson BA. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. Expert Opin Pharmacother. 2006;7:1065-1073.
97. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56:719-724.
98. Ozawa H, Takashima S. Immunocytochemical development of transferrin and ferritin immunoreactivity in the human pons and cerebellum. J Child Neurol. 1998;13:59-63.
99. Wilson MA, Tonegawa S. Synaptic plasticity, place cells and spatial memory: study with second generation knockouts. Trends Neurosci. 1997;20:102-106.
100. Ferry B, Magistretti PJ, Pralong E. High potency of the orally-active NMDA-receptor antagonist CGP 40 116 in inhibiting excitatory postsynaptic potentials of rat basolateral amygdala neurones in vitro. Neuropharmacology. 1997;36:1555-1559.
101. Bardo MT. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol. 1998;12:37-67.
102. Koob GF, Weiss F. Neuropharmacology of cocaine and ethanol dependence. Recent Dev Alcohol. 1992;10:201-233.
103. Mogenson GJ, Wu M, Jones DL. Locomotor activity elicited by injections of picrotoxin into the ventral tegmental area is attenuated by injections of GABA into the globus pallidus. Brain Res. 1980;191:569-571.
104. Mulder AB, Nordquist RE, Orgut O, Pennartz CM. Learning-related changes in response patterns of prefrontal neurons during instrumental conditioning. Behav Brain Res. 2003;146:77-88.
105. Floresco SB, Grace AA. Gating of hippocampal-evoked activity in prefrontal cortical neurons by inputs from the mediodorsal thalamus and ventral tegmental area. J Neurosci. 2003;23:3930-3943.
106. Bast T, Feldon J. Hippocampal modulation of sensorimotor processes. Prog Neurobiol. 2003;70:319-345.
107. Legault M, Congar P, Michel FJ, Trudeau LE. Presynaptic action of neurotensin on cultured ventral tegmental area dopaminergic neurones. Neuroscience. 2002;111:177-187.
108. Vorel SR, Liu X, Hayes RJ, Spector JA, Gardner EL. Relapse to cocaine-seeking after hippocampal theta burst stimulation. Science. 2001;292:1175-1178.
109. Yang CR, Mogenson GJ. Ventral pallidal neuronal responses to dopamine receptor stimulation in the nucleus accumbens. Brain Res. 1989;489:237-246.
110. Swerdlow NR, Braff DL, Geyer MA. GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats Brain Res. 1990;532:146-150.
111. Pittaluga A, Feligioni M, Ghersi C, Gemignani A, Raiteri M. Potentiation of NMDA receptor function through somatostatin release: a possible mechanism for the cognition-enhancing activity of GABA(B) receptor antagonists. Neuropharmacology. 2001;41:301-310,
112. Pittaluga A, Pattarini R, Feligioni M, Raiteri M. N-methyl-D-aspartate receptors mediating hippocampal noradrenaline and striatal dopamine release display differential sensitivity to quinolinic acid, the HIV-1 envelope protein gp120, external pH and protein kinase C inhibition. J Neurochem. 2001;76:139-148.
113. Chiamulera C, Epping-Jordan MP, Zocchi A, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci. 2001;4:873-874.
114. Druhan JP, Wilent WB. Effects of the competitive N-methyl-D-aspartate receptor antagonist, CPR on the development and expression of conditioned hyperactivity and sensitization induced by cocaine. Behav Brain Res. 1999;102:195-210.
115. Mathe JM, Nomikos GG, Schilstrom B, Svensson TH. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res. 1998;51:583-592.
116. Takahata R, Moghaddam B. Target-specific glutamatergic regulation of dopamine neurons in the ventral tegmental area. J Neurochem. 2000;75:1775-1778.
117. Tsai G, Coyle JT. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med. 1998;49:173-184.
118. Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry. 1995;152:332-340.
119. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry. 2001;62(suppl 20):42-48.
120. Ait-Daoud N, Malcolm RJ Jr, Johnson BA. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav. 2006;31:1628-1649.
121. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677-1685.
122. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med. 2005;165:1600-1605.
123. Whiting PJ. The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003;6:648-657.
124. Somogyi P, Tamas G, Lujan R, Buhl EH. Salient features of synaptic organisation in the cerebral cortex. Brain Res Brain Res Rev. 1998;26:113-135.
125. Squires RF, Benson DI, Braestrup C, et al. Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors. Pharmacol Biochem Behav. 1979;10:825-830.
126. Squires RF, Brastrup C. Benzodiazepine receptors in rat brain. Nature. 1977;266:732-734.
127. Whiting PJ. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today. 2003;8:445-450.
128. Ator N. Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr. 2005;10:31-39.
129. Bettler B, Kaupmann K, Bowery N. GABAB receptors: drugs meet clones. Curr Opin Neurobiol. 1998;8:345-350.
130. Kaupmann K, Huggel K, Heid J, et al. Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997;386:239-246.
131. Dawson GR, Collinson N, Atack JR. Development of subtype selective GABAA modulators. CNS Spectr. 2005;10:21-27.
132. Koob GF. A role for GABA mechanisms in the motivational effects of alcohol. Biochem Pharmacol. 2004;68:1515-1525.
133. Heimer L, Alheid GF. Piecing together the puzzle of basal forebrain anatomy. Adv Exp Med Biol. 1991;295:1-42.
134. Koob GF, Roberts AJ, Schulteis G, et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res. 1998;22:3-9.
135. Grobin AC, Matthews DB, Devaud LL, Morrow AL. The role of GABA(A) receptors in the acute and chronic effects of ethanol. Psychopharmacology (Berl). 1998;139:2-19.
136. Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone. a review of case reports and epidemiological data. Addiction. 2003;98:1371-1378.
137. Lhuillier L, Mombereau C, Cryan JF, Kaupmann K. GABA(B) receptor-positive modulation decreases selective molecular and behavioral effects of cocaine. Neuropsychopharmacology. In press.
138. Slattery DA, Markou A, Froestl W, Cryan JF. The GABAB receptor-positive modulator GS39783 and the GABAB receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intracranial self-stimulation studies in the rat. Neuropsychopharmacology. 2005;30:2065-2072.
139. Weerts EM, Froestl W, Griffiths RR. Effects of GABAergic modulators on food and cocaine self-administration in baboons. Drug Alcohol Depend. 2005;80:369-376.
140. Haney M, Hart CL, Foltin RW. Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology. 2006;31:1814-1821.
141. Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry. 2003;64:1440-1448.
142. Assadi SM, Radgoodarzi R, Ahmadi-Abhari SA. Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]. BMC Psychiatry. 2003;3:16.
143. Gardner EL, Schiffer WK, Horan BA, et al. Gamma-vinyl GABA, an irreversible inhibitor of GABA transaminase, alters the acquisition and expression of cocaine-induced sensitization in male rats. Synapse. 2002;46:240-250.
144. Stromberg MF, Mackler SA, Volpicelli JR, O'Brien CP, Dewey SL. The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat. Pharmacol Biochem Behav. 2001;68:291-299
145. Brodie JD, Figueroa E, Laska EM, Dewey SL. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 2005;55:122-125.